These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27569082)

  • 21. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
    Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F
    Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma.
    Sasaki H; Shimizu S; Tani Y; Shitara M; Okuda K; Hikosaka Y; Moriyama S; Yano M; Fujii Y
    Lung Cancer; 2013 Oct; 82(1):51-4. PubMed ID: 23927882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
    Capper D; Preusser M; Habel A; Sahm F; Ackermann U; Schindler G; Pusch S; Mechtersheimer G; Zentgraf H; von Deimling A
    Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal carcinoma and can be utilized in the detection of poorly differentiated colorectal serrated adenocarcinoma.
    Sajanti S; Sirniö P; Väyrynen JP; Tuomisto A; Klintrup K; Mäkelä J; Ristimäki A; Mäkinen MJ
    Virchows Arch; 2014 Jun; 464(6):637-43. PubMed ID: 24722974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
    Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E
    J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations.
    Na JI; Kim JH; Kim HJ; Kim HK; Moon KS; Lee JS; Lee JH; Lee KH; Park JT
    Virchows Arch; 2015 Aug; 467(2):155-68. PubMed ID: 25894433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF
    Grillo F; Paudice M; Pigozzi S; Dono M; Lastraioli S; Lugaresi M; Bozzano S; Tognoni C; Ali M; Sciallero S; Puccini A; Fassan M; Mastracci L
    Histopathology; 2024 Apr; 84(5):877-887. PubMed ID: 38173291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
    Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
    Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
    Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors.
    Hayashi Y; Sasaki H; Takeshita S; Nishikawa R; Nishikawa H; Arakawa A; Yamashita Y; Takahashi S; Sugiura-Ogasawara M
    Oncol Rep; 2014 Nov; 32(5):1815-9. PubMed ID: 25174456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.
    Liu H; Li Z; Wang Y; Feng Q; Si L; Cui C; Guo J; Xue W
    Pathol Int; 2014 Dec; 64(12):601-6. PubMed ID: 25359093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: demonstration by allele-specific PCR/direct sequencing and immunohistochemistry.
    Méhes G; Irsai G; Bedekovics J; Beke L; Fazakas F; Rózsa T; Kiss C
    Am J Surg Pathol; 2014 Dec; 38(12):1644-8. PubMed ID: 25118810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF-V600E immunohistochemistry in a large series of glial and glial-neuronal tumors.
    Breton Q; Plouhinec H; Prunier-Mirebeau D; Boisselier B; Michalak S; Menei P; Rousseau A
    Brain Behav; 2017 Mar; 7(3):e00641. PubMed ID: 28293477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
    Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
    Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of BRAF V600E mutant protein in epithelial ovarian tumors.
    Preusser M; Capper D; Berghoff AS; Horvat R; Wrba F; Schindl M; Schoppmann SF; von Deimling A; Birner P
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):159-64. PubMed ID: 22820660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Molecular features of metanephric adenoma and their values in differential diagnosis].
    Wang X; Shi SS; Yang WR; Ye SB; Li R; Ma HH; Zhang RS; Lu ZF; Zhou XJ; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2017 Jan; 46(1):38-42. PubMed ID: 28072975
    [No Abstract]   [Full Text] [Related]  

  • 39. Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients.
    Ilie M; Long E; Hofman V; Dadone B; Marquette CH; Mouroux J; Vignaud JM; Begueret H; Merlio JP; Capper D; von Deimling A; Emile JF; Hofman P
    Ann Oncol; 2013 Mar; 24(3):742-8. PubMed ID: 23131393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of BRAF V600E (VE1) immunochemistry for the detection of BRAF V600E mutation in non-small cell lung carcinoma cytology specimens.
    Garcia A; Rivera Rolon MDM; Barkoh B; Chen W; Luthra R; Roy-Chowdhuri S
    Cancer Cytopathol; 2023 Jan; 131(1):50-57. PubMed ID: 36200799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.